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Other labs have previously reported the ability of 
adeno-associated virus serotype 9 (AAV9) to cross the 
blood-brain barrier (BBB). In this report, we carefully 
characterized variables that might affect AAV9’s effi-
ciency for central nervous system (CNS) transduction in 
adult mice, including dose, vehicle composition, man-
nitol coadministration, and use of single-stranded versus 
self-complementary AAV. We report that AAV9 is able 
to transduce approximately twice as many neurons as 
astrocytes across the entire extent of the adult rodent 
CNS at doses of 1.25 × 1012, 1 × 1013, and 8 × 1013 vg/kg. 
Vehicle composition or mannitol coadministration had 
only modest effects on CNS transduction, suggesting 
AAV9 crosses the BBB by an active transport mechanism. 
Self-complementary vectors were greater than tenfold 
more efficient than single-stranded vectors. When this 
approach was applied to juvenile nonhuman primates 
(NHPs) at the middle dose (9–9.5 × 1012 vg/kg) tested 
in mice, a reduction in peripheral organ and brain trans-
duction was observed compared to mice, along with a 
clear shift toward mostly glial transduction. Moreover, 
the presence of low levels of pre-existing neutralizing 
antibodies (NAbs) mostly occluded CNS and peripheral 
transduction using this delivery approach. Our results 
indicate that high peripheral tropism, limited neuronal 
transduction in NHPs, and pre-existing NAbs represent 
significant barriers to human translation of intravascular 
AAV9 delivery.
Received 10 December 2010; accepted 20 March 2011; published online 
12 April 2011. doi:10.1038/mt.2011.72
IntroductIon
A significant barrier to central nervous system (CNS) gene 
delivery is the blood-brain barrier (BBB), which prevents large 
or hydrophobic molecules such as viruses, large drugs, and 
many proteins from passively crossing into the brain. The BBB 
consists of three layers that separate the brain/spinal cord and 
cerebrospinal fluid from the blood, and is primarily localized 
to the unique tight junctions of endothelial cells.1,2 These lay-
ers, called the cerebral capillary endothelium, choroids plexus 
epithelium, and arachnoid membranes, are each composed of a 
layer of cells connected by tight junctions. As early as 2003, tran-
sient disruption of the BBB with mannitol was reported to allow 
adeno-associated virus serotype 2 (AAV2) transduction of neu-
ral cells after intravenous  delivery.3–5 Interestingly, recent reports 
have demonstrated some ability of AAV9 and AAV6 to enter the 
CNS following intravenous (i.v.) delivery without the use of any 
BBB-permeabilizing agents.6–9 Particularly with AAV9, there is 
conflicting data on whether neurons are transduced after intra-
venous delivery in adults. Moreover, most of the descriptions are 
focused on spinal cord delivery. Duque et al. reports 5–19% of 
motor neurons transduced in adult mice at a dose of 1 × 1014 viral 
genomes (vg)/kg,6 whereas Foust et al. reports ~5% at a higher 
dose of 2 × 1014 vg/kg.7 Encouragingly, AAV9 was also shown to 
transduce neural cells after intravenous delivery in adult cats6 and 
one newborn cynomolgus macaque.9 Although not described in 
either report, a potential limitation of this approach is the high 
degree of vector delivery to organs outside the CNS such as liver, 
heart, kidney, and skeletal muscle.10
The existing reports on AAV intravascular delivery to the 
brain have all used self-complementary (sc) AAV vectors, which 
utilize a mutant AAV2 inverted terminal repeat on one side of the 
transgene, to package two complementary copies of the transgene 
linked in cis with the mutant inverted terminal repeat and flanked 
by wild-type AAV2 inverted terminal repeats.11,12 scAAV vectors 
are 10–100-fold more efficient than traditional single-stranded 
(ss) AAV vectors, but they have the capacity to package only about 
2.2 kb of foreign DNA, compared to 4.5 kb for ssAAV vectors.
In this study, we sought to investigate in detail the variables 
that might influence the efficiency of AAV9 delivery to the CNS, 
for research or translational purposes. These include the potential 
effects of mannitol or the buffer formulation of the vector vehicle 
on delivery efficiency. To assess the true packaging constraints 
with this approach, we compared ssAAV vectors to scAAV vec-
tors. We also sought to examine variables that would influence 
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the translational feasibility of an AAV9 intravascular approach, 
namely the vector biodistribution, dose response, and efficacy in 
adult mice and juvenile nonhuman primates (NHPs).
results
AAV9 achieves robust delivery to neurons  
and glia after i.v. cns delivery in adult mice
To assess the ability of AAV9 to transduce neural cells after 
i.v. delivery, adult mice were injected, via the tail vein, with 
either 2.5 × 1010, 2 × 1011, or 1.6 × 1012 vg of scAAV9/CBh-GFP 
(1.25 × 1012, 1 × 1013, and 8 × 1013 vg/kg, respectively). Four weeks 
later, mice were killed and assessed for brain and spinal cord 
transduction and vector biodistribution. We also tested AAV1, 
AAV5, AAV6, and AAV8 for CNS transduction after tail vein 
injection compared to AAV9. Although AAV6 displayed a small 
level of CNS transduction and AAV8 was somewhat better, none 
of these serotypes were as efficient as AAV9 (Supplementary 
Figure S1). After AAV9 delivery, green fluorescent protein (GFP) 
positive cells were visible in unstained brain and spinal cord 
sections by viewing native GFP fluorescence (data not shown). 
However, GFP immunohistochemistry (IHC) coupled with a 
Vectastain ABC secondary detection kit provided greater sen-
sitivity with minimal background (Supplementary Figure S2). 
Transduction of all brain areas and spinal cord was apparent in a 
dose-responsive manner with AAV9, with neurons outnumber-
ing astrocytes in the hippocampus (2.0:1) and striatum (1.9:1), 
but not cortex (1.0:1) (Figures 1,2 and 3, Supplementary Table 
S2 and Supplementary Figures S3–S8). As expected, structures 
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Figure 1 dose response of mouse central nervous system (cns) transduction and biodistribution of adeno-associated virus serotype 9 
(AAV9). (a) Mice were injected with scAAV9/CBh-GFP at the indicated doses, then killed 4 weeks later for quantitative PCR biodistribution and 
immunohistochemistry to detect green fluorescent protein (GFP) in the (b) hippocampus, (c) striatum, (d) cerebellum, and (e) spinal cord. In b–e, 
the left panel shows 2.5 × 1010 vg (1.25 × 1012 vg/kg), the middle panel shows 2 × 1011 vg (1 × 1013 vg/kg), and the right panel shows 1.6 × 1012 vg 
(8 × 1013 vg/kg). All 3,3′-diaminobenzidine tetrachloride (DAB) staining reactions were done in parallel for the same amount of time. In a, error bars 
indicate standard deviation. (b–e) Bar = 200 µm. Negative control tissue, magnified images, and longer DAB exposures for the high dose are provided 
as Supplementary Figures S2–S8. Fold expression values and corresponding P values of organs relative to the brain and spinal cord can be found 
in Supplementary Table S1.
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outside of the BBB (such as the median eminence, Figure 3f) 
show higher overall transduction. Co-immunofluourescent label-
ing with antibodies against glial fibrillary acidic protein (astro-
cytes), NeuN (neurons), calbindin (Purkinje neurons), and ChAT 
(motor neurons) showed that AAV9 efficiently transduced a mix 
of mostly neurons and astrocytes (Figure 4). A small degree of 
co-labeling was also seen between GFP and Olig1 (oligodendro-
cytes), but not CD11b (microglia) (data not shown). From the 
same mice, portions of the brain, spinal cord, liver, heart, kid-
ney, spleen, ovary, and gastrocnemius muscle were used for DNA 
extraction and quantitation of the GFP transgene by quantitative 
PCR (qPCR, Figure 1). All GFP quantitation was normalized to 
the quantitation of a genomic reference in the laminB2 locus, to 
determine the number of GFP copies per diploid mouse genome. 
The kidney, brain, and spinal cord biodistribution escalated in a 
linear fashion correlating with dose. Other tissues, in particular 
the liver, spleen, lung, and skeletal muscle, did not follow a linear 
escalation of GFP copies correlating to dose, indicating possible 
saturation of AAV9’s transduction capability in these tissues at 
the middle or high dose.
the vehicle composition, but not mannitol, affects 
AAV9 cns transduction and biodistribution
Mannitol can aid large molecules to passively enter the CNS, by 
transiently loosening the tight junctions between endothelial cells. 
To test whether mannitol preinjection can help AAV9’s penetra-
tion of the CNS as it can for AAV2,4,5 adult mice were injected 
in the tail vein with 2 × 1011 vg (1 × 1013 vg/kg) of scAAV9/CBA-
GFP with or without a prior tail vein injection of a 25% mannitol 
solution (200 μl). After 4 weeks, the mice were killed and their 
brains were taken for qPCR biodistribution. As assessed by copies 
of GFP per diploid mouse genome, coadministration of mannitol 
8 minutes prior to AAV injection resulted in only a 50% increase 
in brain delivery (Figure 5a). Time points of 1, 5, and 10 minutes 
were also tested with little to no effect on AAV9 CNS transduction 
(data not shown).
To test whether the vehicle solution of AAV9 might affect 
the CNS transduction and/or biodistribution, a stock solution of 
scAAV9/CMV-GFP in a buffer of 1 × phosphate-buffered saline 
(PBS), 5% sorbitol, and 213 mmol/l added NaCl (350 mmol/l 
final NaCl concentration) was diluted to the final buffer com-
positions shown in Figure 5b. Then 1 × 1011 vg (5 × 1012 vg/kg) 
was injected via the tail vein into adult mice. After 4 weeks, the 
mice were killed and the brains and spinal cords were recovered 
for qPCR biodistribution. The presence of 5% sorbitol in the 
vehicle increased transduction in the CNS approximately two-
fold. Increasing the vehicle NaCl concentration up to 350 mmol/l 
further enhanced AAV delivery to the brain and spinal cord, but 
this effect was lost as the NaCl concentration was increased to 
480 mmol/l. These results demonstrate that modifying the AAV9 
vehicle composition can result in greater than a threefold change 
in brain delivery after tail vein injection in adult mice.
scAAV9 is much more efficient than ssAAV9  
for intravascular cns delivery
The 2.2 kb packaging constraints of scAAV vectors set strict 
size limits on the genes that could be delivered to the brain by 
an intravascular approach for research or therapeutic purposes. 
To test the ability of ssAAV vectors to deliver a larger transgene 
to the brain by this approach, 5 × 1011 vg (2.5 × 1013 vg/kg) of 
ssAAV9/CMV-GFP was injected into the tail vein of adult mice. 
After 4 weeks, the mice were killed and their brains and spinal 
cords were sectioned for IHC against GFP. Although some trans-
duction of cells with neuronal and glial morphology was visible 
Figure 2 efficient transduction of neurons and glia in the mouse hippocampus. Enlarged image of Figure 1b, right panel. Bar = 200 µm. 
Arrowheads indicate examples of cells with neuronal (black) or glial (white) morphology.
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in the brain and spinal cord, it was highly reduced compared to 
scAAV9 vectors (Supplementary Figure S9). The number of 
GFP-positive cells were similar to those seen with a 20-fold lower 
dose of 2.5 × 1010 vg of scAAV9 (Figure 1), demonstrating the 
greater efficacy of scAAV9 over ssAAV9.
GFP, but not AAV9, causes transient liver toxicity  
in mice after i.v. AAV9 administration
To assess the potential consequences of AAV9 intravascular 
administration and gene expression in naive mice, we injected 
adult mice with either 2.4 × 1011 vg of ssAAV9/CBA-GFP or 
3 × 1011 vg of ssAAV9/CBA-GAN. The giant axonal neuropa-
thy (GAN) construct packages the coding sequence for the pro-
tein gigaxonin, which is missing in patients with GAN.13,14 At 1, 
2, 4, 8, 12, and 16 weeks after virus administration, blood was 
collected and used to measure serum levels of albumin (gen-
eral inflammation), blood urea nitrogen (kidney toxicity), and 
alanine amino transferase (ALT, liver toxicity). Weight mea-
surements were also taken at regular intervals up to 60 weeks 
postinjection, and a group was killed at 4 weeks postinjection 
to assess vector biodistribution. These results are summarized 
in Figure 6. Neither GFP nor GAN AAV9 vectors caused any 
significant change in albumin or blood urea nitrogen levels. 
However, the GFP vector (but not GAN) caused a transient rise 
in ALT levels that correlated to a significant decrease in GFP 
genomes detected in the liver. There was no difference in weight 
between the groups, suggesting that the transient liver toxicity 






Figure 3 Broad distribution of neuronal and glial transduction across the mouse central nervous system (cns). Representative images showing 
immunohistochemistry using an anti-green fluorescent protein (GFP) antibody on coronal brain and spinal cord sections. These were taken from the 
same set of mice depicted in Figure 1, at the 2 × 1011 vg dose (scAAV9/CBh-GFP injected i.v. in adult mice). (a–i) Filled scale bars are 100 µm, and 
(j,k) open scale bars are 1 mm. Filled black arrowheads indicate examples of cells with neuronal morphology, and open (white) arrowheads indicate 
examples of cells with astrocytic morphology. (a) Primary motor cortex, (b) piriform cortex, (c) hypothalamus, (d) thalamus, (e) medulla, (f) arcu-
ate nucleus and median eminence, (g) amygdala, (h) caudal hippocampus, (i) ventral horn of the cervical spinal cord, (j) coronal section, bregma 
−1.9 mm, (k) coronal section, bregma −6.2 mm.
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the success of AAV9 intravascular delivery  
in juvenile nHPs is dependent on the absence  
of pre-existing nAbs
To determine whether systemic delivery of AAV9 to NHPs would 
result in transduction of CNS cells as it does in mice, we con-
ducted a comparison of scAAV9/CBh-GFP transduction efficiency 
when delivered either by i.v. (saphenous vein, 9 × 1012 vg/kg) or 
intra-arterial injection (i.c., carotid artery, 9–9.5 × 1012 vg/kg) in 
3–4-year-old male rhesus macaques. Two animals were injected 
by each route, and one i.c. animal (#26706) had a low (1:4) titer 
of pre-existing AAV9 NAbs. All animals tolerated the procedure 
well and were in good health until the end of the study. Four weeks 
after virus infusion, the animals were euthanized and their brains, 
spinal cords, and several peripheral organs were rapidly dissected 
and processed for molecular analysis, IHC, and co-IF analysis. 
GFP immunostaining showed one i.v. NHP (#26945) and one i.c. 
NHP (#26149) had efficient brain transduction, whereas the other 
two showed minimal brain transduction (i.c. #26706, i.v. #26165, 
Figure 7). Based on morphology and co-IF, it appears that most 
GFP-expressing (GFP+) cells in the brain are astrocytes, which 
outnumber neurons in the hippocampus (4:1), frontal and pari-
etal cortices (an average of 30:1 and 11:1, respectively), but not in 
the cerebellum (1:1) (Figures 7 and 8, Supplementary Table S2, 
and Supplementary Figures S10–S12).
Since NHP 26706 had a pre-existing NAb titer of 1:4, we 
hypothesized that the poor CNS transduction might be related 
to an anti-AAV immune response, as has been reported for liver 
transduction.15,16 To test this, sera collected at preinjection and 1, 
2, and 4 weeks postinjection were examined for AAV9 NAbs. The 
NHPs 26149 and 26945, with high transduction, had peak NAbs of 
1:32 and 1:64, whereas the i.c. NHP (26706) with minimal trans-
duction had a peak NAb titer of 1:512 (Table 1). Interestingly, the 
NAb titer of the i.v. NHP with lower transduction (26165) was 
low on week 1 (1:64) and kept rising through week 4 (1:256). 
Correlating with the presence of pre-existing AAV9 NAbs and the 
hypothesis of NAb-mediated clearance of AAV9 particles, there 
was a 100-fold decrease in circulating AAV vector genomes at 6 
hours postinjection in NHP 26706 with a 1:4 titer of pre-existing 
NAbs, and no vector genomes were detected at 24 hours postinjec-
tion, compared with 1.3 × 106 to 2.6 × 106 vg for the three animals 
without pre-existing NAbs (Supplementary Table S3). The low 
transduction of NHP 26165, which had no detectable pre-exist-
ing NAb but a gradually increasing NAb titer postinjection, had 
serum titers of AAV particles equivalent to the highly transduced 
NHPs (26945 and 26149), which suggest a different mechanism to 
limit transduction than rapid clearance from the blood.
In peripheral tissues, the liver, heart, and adrenals were highly 
transduced, whereas the kidney, spleen, and testes expressed 
lower levels of GFP (Figure 9). Except for NHP 26706 with pre-
existing NAbs, qPCR analysis of AAV9 vector genome biodistri-
bution generally correlated with the GFP expression seen by IHC 
(Figure 9). The i.c.-injected animal with detectable pre-existing 
NAbs (26706) had little GFP in any peripheral organs, with qPCR 
showing the highest concentration of vector genomes in the spleen. 
Interestingly, by peripheral GFP expression and vector biodistri-
bution NHP 26165 showed no apparent deficits, even though CNS 
transduction was highly reduced and there was a high concentra-
tion of vector genomes in the spleen.
dIscussIon
Intravascular AAV9 delivery to the CNS could possibly have enor-
mous clinical relevance for a number of diseases, such as lysosomal 
storage diseases and spinal muscular atrophy. The use of the vascula-
ture allows even and widespread CNS gene delivery with a minimally 
invasive procedure. However, previous studies do not adequately 








































Figure 4 Adeno-associated virus serotype 9 (AAV9) transduces a 
variety of cell types after i.v. delivery to the mouse central nervous 
system (cns). (a–f) Alternate serial sections described in Figure 1 were 
subjected to co-immunofluorescence with the indicated antibodies. For 
each set of three panels, the left panel shows green fluorescent protein 
(GFP) expression, the middle shows labeling with the indicated anti-
body, and the right panel shows a merged image. The inset in the right 
panel highlights co-localization observed, and the arrow points to the 
cells magnified. All images are four merged confocal Z-stacks of samples 
from mice injected with 2 × 1011 vg (1 × 1013 vg/kg), except for panel 
f which shows the 1.6 × 1012 vg (8 × 1013 vg/kg) dose. Note that with 
panel e, native fluorescence was used to visualize GFP expression. Scale 
bars for all panels are shown in the right panels. Bar = 200 µm.
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delivery to the CNS. To bridge this gap, we report the ability of AAV9 
to transduce neurons and glia in the brain and spinal cord of mice and 
NHPs, along with a quantitation of the dose-responsive delivery to 
peripheral organs. We also report the efficacy of AAV9 CNS transduc-
tion in juvenile NHPs, and the importance of pre-existing NAbs (or 
more correctly, lack thereof) for efficient intravascular CNS delivery.
An important consideration for any systemic CNS delivery 
strategy is the amount of vector that enters non-CNS organs. In 
a recent clinical trial for hemophilia B, the capsid of a rAAV2/
factor IX vector delivered to the liver elicited an asymptom-
atic immune clearance of the vector at doses of 4 × 1011 vg/kg or 


















































167 mmol/l PBS + 0.7% sorbitol
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350 mmol/l PBS + 5% sorbitol
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a b
Figure 5 Mannitol and vehicle can modestly affect adeno-associated virus serotype 9 (AAV9) mouse central nervous system (cns) delivery. 
In each case, mice received a tail vein injection of 1×1011 vg (5×1012 vg/kg) of scAAV9/GFP. After 4 weeks, tissues were harvested, and extracted DNA 
tested by quantitative PCR as described in the methods. (a) Mice received an intravenous (i.v.) injection of mannitol 8 minutes prior to i.v. vector 
injection. (b) A virus stock was diluted to create the vehicle compositions shown, then intravenously injected into mice. Error bars indicate standard 








































































































































Figure 6 AAV9/GFP, but not AAV9/GAn, vectors show a transient liver toxicity and reduction in vector genomes. Mice were injected with 
either ssAAV9/CBA-GFP (n = 6) or ssAAV9/CBA-GAN (n = 8). (a) Just after the 4-week time point postinjection, a group of mice (n = 3 green fluores-
cent protein (GFP), n = 4 giant axonal neuropathy (GAN)) was killed to assess biodistribution by quantitative PCR. In panels b–e, the arrow denotes 
the time when these mice were removed from the cohorts. (b) Weights were taken at the indicated time points and expressed relative to the starting 
weight. Serum was collected at the indicated time points and tested for levels of (c) albumin, (d) blood urea nitrogen (BUN), and (e) alanine amino 
transferase (ALT). All error bars indicate standard deviation. *Significantly higher value with P < 0.05 (Student’s t-test: two-tailed, unpaired, equal 
variance). AAV9, adeno-associated virus serotype 9.
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immune response was not observed in the muscle at doses up to 
1.8 × 1012 vg/kg, where the rAAV2 vector was well tolerated and 
transgene expression persisted for over 3 years.18,20,21 The experi-
ence gained from these hemophilia clinical trials suggests liver, but 
not muscle, transduction as a major barrier to systemic delivery 
in humans, a finding that was not originally predicted by animal 
models. In our mouse studies, AAV9 showed the highest tropism 
for liver, followed by the kidney and spleen. Regardless of dose, the 
transduction efficiency of AAV9 for CNS delivery was consider-
ably lower than for peripheral organs. Interestingly, although the 
biodistribution in the brain and spinal cord increased as a func-
tion of dose, biodistribution in the liver only increased in approxi-
mately twofold increments whereas the dose increased in eightfold 
increments. This could suggest that although AAV9 receptors did 
not become saturating in the brain and other tissues, AAV9 recep-
tors in the liver were saturated at higher doses. Although our data 
do not exclude this possibility, the observed transient rise of ALT 
in serum (Figure 6e) suggests, instead, that many AAV9 particles 
have entered the liver and been cleared, and the AAV9 biodistribu-
tion we observed at 4 weeks is an underestimate of the total AAV 
genomes that were delivered. In agreement with this hypothesis, 
when we previously reported GFP biodistribution in mice with 
AAV9 at 10 days postinjection at 5 × 1010 vg/mouse,22 there were 
30.6 copies of GFP per diploid mouse genome. In this study, look-
ing at 4 weeks postinjection, only 1.2 and 2.8 copies of GFP/genome 
were detected at vector doses of 2 × 1011 and 1.6 × 1012 vg/mouse, 
respectively (Figure 1). A transient rise in ALT levels was observed 
when the transgene was GFP but not gigaxonin, and this corre-
lated with less copies of GFP in the liver after 4 weeks (Figure 6a), 
suggesting that GFP was the toxic agent rather than AAV9. Since 
GFP is a foreign protein and mice would be pre-exposed to their 
own gigaxonin epitopes (98% identical to human), it is reasonable 
to propose that AAV9 liver transduction might lead to a cytotoxic 
T lymphocytes-mediated clearance of GFP-expressing cells. This 
effect might be a consequence of the mouse strain used, since 
BALB/c mice are particularly sensitive to a transgene-specific and 
cytotoxic T lymphocyte-mediated clearance of hepatocytes.23 The 
loss of GFP expression might also be a consequence of the serotype 
used, as Lu and Song demonstrated that AAV1 elicited strong cellu-
lar and humoral immune responses to its transgene whereas AAV8 
did not, and this difference was attributed to AAV1’s tropism for 
dendritic cells.24 It is unknown whether AAV9 transduces dendritic 
cells in vivo. Although we cannot comment directly on whether 
GFP toxicity was a result of GFP protein accumulation or an anti-
GFP immune response, the observation of transient transgene-
related liver toxicity certainly raises a concern over using AAV9 
intravascular delivery to transduce the CNS. The implications of 
high vector delivery to peripheral organs relative to the CNS need 
to be addressed in any translational approach. Promising develop-
ments in vector design22,25,26 suggest that new vectors could be engi-
neered to limit peripheral tropism and circumvent this concern, 
particularly with liver-detargeting mutations identified in AAV9.27
This study provided a unique opportunity to assess AAV9 
performance in adult mice compared to young adult NHPs. The 

















Figure 7 Intravascular injection of adeno-associated virus serotype 9 (AAV9) in nonhuman primates (nHPs) results in broad central nervous 
system central nervous system (cns) transduction that is limited by an anti-AAV9 immune response. NHPs were injected with scAAV9/CBh-
GFP via the carotid artery (i.c., animals 26149 and 26706) or the saphenous vein (intravenous, animals 26945 and 26165). Green fluorescent protein 
(GFP) biodistribution was assessed by immunohistochemistry 4 weeks after injection. Examples of GFP expression detected by 3,3′-diaminobenzidine 
tetrachloride staining in the cortex, hippocampus, cerebellum, dorsal (D) and ventral (V) spinal cord are shown for each animal. Arrows point to 
GFP-positive cells highlighted in the magnified insets with neuronal (short arrow) or glial (long arrow) morphology. An asterisk (*) denotes that NHP 
26706 had detectable pre-existing neutralizing antibodies (see Table 1). Bar = 100 µm.
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dose used in our NHP studies was 0.9–0.95 × 1013 vg/kg, which 
is similar to the 1 × 1013 vg per kg dose injected into the 20 g 
mice in our study. In our studies, we observed extensive trans-
duction of neurons and glia throughout the brain and spinal 
cord in mice, with neurons outnumbering astrocytes ~2:1 in the 
hippocampus and striatum, and 1:1 in the cortex (Figures 1–3, 
and Supplementary Table S2). These results were different from 
what we found in NHPs, where the overall transduction efficiency 
was considerably lower and there was mostly glial transduction 
(see Supplementary Table S2). Our qPCR data showed that at 
comparable doses (~1 × 1013 vg/kg), mice had 0.17 (+/− 0.03 SD) 
























































Figure 9 nonhuman primate (nHP) biodistribution and expression in 
peripheral organs. At the time of euthanasia, various peripheral organs 
were rapidly dissected and frozen in liquid nitrogen for quantitative PCR 
(qPCR) analysis of vector genome biodistribution (top panel) or post-
fixed in 4% paraformaldehyde and processed for immunohistochemical 
detection of green fluorescent protein (GFP) by 3,3′-diaminobenzidine 
tetrachloride staining (bottom panel). For the qPCR biodistribution stud-
ies, the “brain” is the average value of three samples and the “spinal 
cord” is the average of cervical and lumbar samples. Bottom: animals 
with no pre-existing antibodies (i.c., 26149; i.v., 26945) showed high 
levels of transduction in the liver, heart, and adrenals whereas the kidney, 
spleen, and testes showed lower levels of GFP expression. The animal 
with pre-existing neutralizing antibodies (NAbs) (i.c., 26706) had no 
observable GFP expression except in the spleen. The fourth NHP showed 
rising levels of NAbs throughout the 4 weeks postadministration and had 
high expression of GFP in the liver, moderate in the heart and adrenals, 
and low in the kidney, spleen and testes. Scale bar for each organ is 
shown in the picture of the control sample. Bar = 100 µm.






































Figure 8 Intravascular adeno-associated virus serotype 9 (AAV9) 
delivery in nonhuman primates (nHPs) transduces mostly glia in 
the central nervous system (cns). Representative sections from the 
NHPs showing higher levels of transduction (left panels: i.c., 26149; 
right panels: i.v., 26945) were selected and subjected to co-immuno-
fluorescence with the indicated antibodies. For each picture, green fluo-
rescent  protein-expressing cells are green and (a–f) glial fibrillary acidic 
protein or (g–l) NeuN-positive cells are red. Control sections in which 
no primary antibodies were used are depicted in (m) green and (n) 
merged green and red. The insets highlight observed co-localization, 
arrows pointing to the magnified cells. Scale bars for all panels are on the 
bottom panels. Bar = 100 µm.
table 1 Anti-AAV9 neutralizing antibody titers of the nonhuman primates used in the study
Animal Id Age (years) Viral titer (vg/kg BW)
neutralizing Ab titer
Preinjection 1 week 2 weeks 4 weeks
26149 (i.c.) 4 9.5 × 1012 <1:2 1:64 1:64 1:64
26706 (i.c.) 3 8.9 × 1012 1:4 1:512 1:256 1:256
26945 (i.v.) 3 8.7 × 1012 <1:2 1:32 1:32 1:32
26165 (i.v.) 4 9.1 × 1012 <1:2 1:64 1:128 1:256
Abbreviations: Ab, antibody; BW, body weight; i.c., intracarotid; i.v., intravenous.
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pre-existing NAbs had significantly less copies per cell in the brain 
(0.039 +/− 0.037 SD, P = 0.009; Figure 9), indicating that there 
is less vector entering or persisting in the brain in NHPs versus 
mice. At this time, it is unclear what caused the reduction in CNS 
delivery and neuronal tropism in NHPs as compared to mice. This 
could be due to any number of species-specific factors including 
differential BBB transport, capsid-interacting blood factors to 
promote or inhibit AAV9 transduction (S. Fedor and L. Garcia, 
Genethon, personal communication, January 2011), neural cell 
tropism within the brain, and/or intracellular trafficking and vec-
tor persistence. In our NHP study, the best CNS and peripheral 
transduction was observed after i.c. delivery in the absence of 
pre-existing NAbs. The variability between the two NHPs show-
ing the highest transduction (i.c. 26149 and i.v. 26945) was more 
than we would normally see with inbred BALB/c mice, but given 
the difficulty of using large numbers of NHP subjects we cannot 
yet comment with confidence on whether the i.c. route of admin-
istration is indeed better or whether this difference is due to vari-
ability between animals. However, these large animal experiments 
do provide a distinct data collection supporting a unique NHP-
specific AAV9 tropism influenced by the route of administration, 
highlighting the need for additional supporting studies before 
testing in patients.
In our laboratory and others, when AAV9 is injected intra-
parenchymally in mice it displays a nearly exclusive neuronal tro-
pism.7,22,28 The shift in AAV9 toward astrocytic tropism therefore 
appears to be a result of the route of administration. We can spec-
ulate that the passage of AAV9 across the BBB would expose it to 
endothelial cells, pericytes, and astrocytic processes before it has 
access to neurons.1 We could further speculate that whether AAV9 
had any ability to transduce these non-neuronal cells, it could 
explain the shift in tropism when changing the delivery route 
from intraparenchymal to intravascular delivery. Alternatively, 
there might be factors in the blood that bind the AAV9 capsid 
and modify its tropism, as has been previously demonstrated with 
liver-specific uptake of adenovirus vectors.29,30 In either case, the 
ineffectiveness of mannitol to enhance AAV9 CNS transduction 
in the mouse suggests that AAV9 employs an active transport 
mechanism across the BBB rather than passively slipping through 
the tight junctions between endothelial cells.
The efficient transduction of mouse neurons in our studies is 
in accordance with what was reported by Duque et al., but incon-
sistent with the report by Foust et al.6,7 We have no explanation 
for why we saw transduction of neurons in the adult mouse brain 
and Foust et al. did not, but in our experiments, we tested three 
different promoters with similar results, one of which (CBA) is 
the same promoter used by Foust et al.7 In addition to the highly 
pure CsCl gradient-purified vector used for all the reported data, 
in the course of our studies we also tested vectors purified by ion-
exchange chromatography, as well as “dirty” vector preparations 
containing high amounts of cellular protein contamination (data 
not shown). We also tested different vehicle compositions and 
multiple doses (Figures 1 and 5). In all cases, we always observed 
transduction of similar ratios of neurons and glia, with the overall 
efficiency primarily dependent on dose. It is our conclusion that 
AAV9 transduces both neurons and glia after intravascular deliv-
ery in adult mice and mostly glia in NHPs.
When discussing the translational feasibility of AAV9 intra-
vascular delivery to large animals and humans, vector dose repre-
sents a significant translational barrier. Manufacturing vector for 
rodent studies (both for basic science and preclinical testing) at 
even a very high dose (2 × 1014 vg/kg) is certainly feasible, and 
this could be valuable in certain research applications to avoid the 
time-consuming generation of transgenic mice. When a dose of 
2 × 1014 vg/kg is needed in a 5 kg NHP, manufacturing 1 × 1015 vg 
per animal becomes a significant logistical challenge, especially 
in a multi-animal study with sufficient numbers for statistical sig-
nificance. Vector needs for application to multiple 20 kg children 
or 80 kg adults becomes prohibitive with current manufacturing 
capabilities. However, the dose of 1 × 1013 vg/kg used in our NHP 
studies may be more reasonable for translation from a manufac-
turing standpoint. As the level of CNS transduction seen at these 
doses is lower than expected when comparing mice to NHPs, fur-
ther studies are warranted to determine whether an AAV9 intra-
vascular approach may be a realistic therapeutic strategy.
Another translational obstacle is the potential for pre-existing 
NAbs to the AAV9 capsid, which is estimated to be present in 
33.5% of the human population.31 Although the number of NHPs 
in our study was too low to draw firm conclusions, two of the 
NHPs showed minimal CNS transduction, and this correlated 
with the highest NAb titers following injection. The NHP 26706 
with the highest peak NAb titer (1:512) also had a low but detect-
able titer of pre-existing NAbs (1:4). The pre-existing NAb titer 
correlated with a more rapid clearance of AAV from the blood, 
as might be expected from previous findings that low NAbs titers 
can block liver transduction in NHPs (1:5)15 and mice (1:10).32 
The uncertainty comes from the second NHP with poor CNS 
transduction, #26165. This NHP had no detectable pre-existing 
NAbs and normal serum titers of circulating AAV9 at 6 and 24 
hours postinjection (relative to the two successfully transduced 
NHPs 26149 and 26945), indicating that there was not an ini-
tial NAb-mediated clearance of vector. Peripheral organ deliv-
ery and transduction were observed, but CNS transduction was 
minimal and there was a gradual rise in AAV9 NAbs following 
the injection. From these results, we might speculate that NHP 
26165 mounted a delayed immune reaction responsible for the 
clearance of transduced cells, or else there was another unknown 
block to CNS transduction in this particular NHP. From our data, 
we cannot conclude whether there was an initial block to CNS/
neural cell infection in NHP 26165, or whether GFP+ cells were 
specifically cleared only from CNS after successful gene delivery. 
All together, our results suggest that even a very low pre-existing 
AAV9 NAb titer presents a clear obstacle to AAV9-mediated 
CNS delivery in NHPs, and that other uncharacterized barriers 
might exist that could limit transduction in NHPs. These known 
and unknown obstacles indicate that further investigation of 
AAV9 NHP tropism and/or additional engineered capsids22,26,33,34 
are warranted before translation of this approach to humans is 
pursued.
In conclusion, we report widespread transduction of neurons 
and glia in the spinal cord and brain of mice after intravenous 
administration of AAV9 and a predominant transduction of 
glia in NHPs after both intravenous and intra-arterial adminis-
tration. The optimization of AAV vectors for intravascular CNS 
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delivery could have important immediate implications for dis-
orders such as lysosomal storage diseases that would employ 
intra-CNS expression of secreted enzymes to break down toxic 
metabolic intermediates, and would not necessarily require high 
neuronal transduction (see reviews).35,36 However, the inability of 
systemically administered AAV9 to efficiently transduce neurons 
in NHPs diminishes the feasibility of this approach for the treat-
ment of human brain diseases, especially those that would require 
efficient neuronal transduction such as spinal muscular atrophy, 
fragile X syndrome, or Rett syndrome. In instances where global 
transduction is desired but there is a need to restrict expression 
to only specific sub-populations of neurons (such as Parkinson’s 
Disease), there would be a clear need to either use a cell-specific 
promoter or to modify the AAV capsid to specifically target those 
cells. Even if AAV9 is not an ideal vector, there is still the poten-
tial for identifying new AAVs, naturally occurring or engineered, 
which would be more appropriate. For example, liver-detargeting 
mutations in AAV9 have been identified that may make it more 
amenable for safe intravascular gene transfer to the CNS.27 While 
the ability of AAV9 to transduce the CNS in juvenile NHPs pro-
vides additional translational relevance to this approach, the con-
sequences of vector delivery to non-CNS organs, low neuronal 
transduction efficiency, and potential interference by pre-existing 
NAbs needs to be addressed.
MAterIAls And MetHods
Virus preparation. rAAV vectors were produced by the University of North 
Carolina Vector Core using a triple-transfection method in HEK293 cells 
as described.37 Highly pure recombinant virus were recovered using two 
sequential CsCl gradients, then the peak fractions were dialyzed in PBS 
containing 5% D-sorbitol, unless otherwise indicated. When scAAV vec-
tors were made, the majority of packaged genomes were full-length self-
complementary (data not shown). Viral titers were determined by both dot 
blot37 and qPCR. The recombinant vectors in these studies utilized several 
packaged transgene cassettes: sc-CBA-GFP, sc-CBh-GFP, sc-CMV-GFP, 
ss-CBA-GFP, and ssCBA-GAN. Details of these constructs can be found in 
Supplementary Table S4.
Quantitative PCR and biodistribution. qPCR was used to determine viral 
titer and for biodistribution studies. Viral and tissue DNA was purified and 
quantitated using SyBR Green as described,22 except for the NHP GAPDH 
qPCR reactions. Note that for the mouse brain, every 5th coronal section 
was pooled and used for DNA extraction. Copies of GFP were assessed in 
each organ sample and normalized to copies of the mouse laminB2 locus 
or copies of the rhesus GAPDH locus, as appropriate (with two copies of 
the genomic reference representing a diploid host genome). NHP GAPDH 
qPCR reactions were done on a Roche 480 Lightcycler instrument using 
the Faststart Taqman Probe Master Mix (catalog # 4673450001; Roche, 
Indianapolis, IN), following the manufacturer’s instructions. The primer 
and probe sequences for GAPDH were as follows: forward: 5′-ggcctcca-
aggagtaagacc-3′, reverse: 5′-tctcttcctcttgtgctctcg-3′, probe: accaccag (cata-
log # 04694155001, probe #131 UPL extension library).
Mouse studies
All investigations were approved by the University of North Carolina–
Chapel Hill Institutional Animal Care and Use Committee. Two hundred 
microliters of vector of the indicated titers of each serotype were injected 
into the tail vein. When mannitol was used, a solution of 200 μl of 
sterile 25% mannitol in water was injected into the tail vein 8 minutes 
prior to virus injection. All injections were done in 8–12-week-old 
female BALB/c mice purchased from Jackson Laboratory (Bar Harbor, 
ME). Four weeks following vector injection, each mouse was killed and 
transcardially perfused with PBS or PBS containing 1 U/ml heparin 
(Abraxis, Schaumburg, IL). Organs were collected and processed for DNA 
extraction or immunolabeling. Blood was collected from mice according 
to Institutional Animal Care and Use Committee guidelines. To collect 
serum, the whole blood was incubated for 2 hours at room temperature 
followed by centrifugation at 1000g for 15 minutes. The supernatant (sera) 
was then stored at −80 °C. Once all sera were collected, they were tested 
for albumin, blood urea nitrogen, and ALT levels by the UNC Animal 
Clinical Laboratory Core Facility.
Immunolabeling and imaging of mouse samples: After 48 hours of 
fixation in freshly made PBS with 4% paraformaldehyde, the entire brain 
and portions of the cervical and lumbar spinal cords were sectioned 
at 40 µm using a Leica vibrating microtome at room temperature. To 
enhance the signal observed with GFP, every 5th section was processed 
for IHC. Samples were incubated for 1 hour at room temperature in 
blocking solution (10% goat serum, 0.1% Triton X-100, 1× PBS), then 
incubated for 48–72 hours at 4 °C in primary antibody solution [3% 
goat serum, 0.1% Triton X-100, 1× PBS, rabbit anti-GFP (# AB5541, 
1:500; Millipore, Billerica, MA)]. After washing three times in 1× PBS, 
secondary amplification was performed using a VectaStain ABC Elite Kit 
(#PK-6101; Vector Labs, Burlingame, CA) with 3,3′-diaminobenzidine 
tetrachloride (#04008; Polysciences, Warrington, PA) substrate and 
nickel-cobalt intensification of the reaction product.
For co-labeling studies, blocking and primary antibody incubations 
were done as described above. After washing, the sections were incubated 
for 1 hour at room temperature in secondary antibody solution (3% goat 
serum, 0.1% Triton X-100, 1× PBS, secondary antibodies), then washed 
three more times in 1× PBS. Primary antibodies were as follows, with 
combinations described in Figure 4: rabbit anti-GFP (1:500, #AB5541; 
Millipore), mouse anti-NeuN (1:500, Millipore #MAB377), goat anti-
ChAT (1:100, #AB144P; Millipore), and rabbit anti-Calbindin (1:500, 
#AB1778; Millipore). Secondary antibodies were as appropriate, each 
at 1:1000 dilution: goat anti-rabbit Alexa 488 (#A11008; Invitrogen, 
Carlsbad, CA), goat anti-mouse Alexa 594 (#A11032; Invitrogen), goat 
anti-rabbit Alexa 594 (#A11037; Invitrogen), donkey anti-goat Alexa 
594 (#A11058; Invitrogen), and donkey anti-rabbit Alexa 594 (#A21206; 
Invitrogen).
Microscopy: Confocal imaging was performed at the Michael Hooker 
Microscopy Center at UNC-Chapel Hill using a Zeiss Axiovert LSM510 
laser confocal microscope. Images were processed using Zeiss LSM 
Image Browser software. Dual-label immunofluorescence images were 
reconstructed from four consecutive steps in a Z-series taken at 1.3 μm 
intervals through the section of interest using a ×20 objective.
3,3′-diaminobenzidine tetrachloride-processed brain sections were 
digitized using a Scan-Scope slide scanner (Aperio Technologies, Vista, 
CA). Virtual slides were viewed using ImageScope software package 
(v. 10.0; Aperio Technologies), which allowed sections to be viewed at 
equivalent magnifications.
NHP studies
Animals and surgeries: Four juvenile (3–4-year-old) male rhesus macaques 
(Macaca mulatta) were used in this study and were cared for by the Division 
of Animal Resources at the Oregon National Primate Research Center in 
accordance with National Institutes of Health guidelines and approved by 
the Institutional Animal Care and Use Committee at OHSU. scAAV9-CBh-
GFP at a dose of 0.9–1 × 1013 vg/kg birth weight was injected in four NHPs 
on day 0 of the protocol, via two different systemic routes of administration 
(intravenous and intracarotid, n = 2). Animals were deeply anesthetized 
with ketamine HCl (10 mg/kg birth weight intramuscular injection) 
and anesthesia was maintained with isoflurane gas vaporized in 100% 
oxygen. For the intravenous injection (n = 2), a percutaneous 22-gauge 
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intravenous catheter was placed in the animal’s right leg saphenous vein 
and flushed with saline to verify correct placement. The virus preparation, 
already diluted with a solution of PBS containing 5% sorbitol to a final 
volume of 10 ml/kg birth weight, was infused over a 15–20-minute period 
at a rate of 2.5 ml/minute. After the infusion was completed, the catheter 
was flushed with saline, removed, and digital pressure was applied on 
the puncture until complete hemostasis. After hemostasis is confirmed, 
each NHP was returned to his home cage for observation and recovery. 
Intracarotid infusion of scAAV9 was performed on two NHPs according 
to the following procedure. After administration of general anesthesia, 
pain transmission was blocked with a local anesthetic line block consisting 
of bupivacaine (0.25%) mixed with lidocaine (1%) and epinephrine 
(1:100,000) administered intradermally along the incision site. Once 
anesthesia was attained, a curvilinear 4 cm skin incision from the ventral 
midline of the neck extending to the medial aspect of the left mandibular 
ramus (condyle) was created. Blunt dissection through the subcutaneous 
tissue was followed by lateral retraction of the sternomastoid muscle, 
revealing the carotid trunk. The cranial nerve X (vagus) was dissected 
free from the common carotid artery, retracted with a vein loop. The right 
carotid trunk was dissected under the mandible to reveal the bifurcation 
of the internal, external, and lingual branches. A Rumel was placed around 
the external and lingual arteries, a 24-gauge catheter was introduced into 
the common carotid and a controlled infusion scAAV9-CBh-GFP diluted 
in PBS containing 5% sorbitol, at 10 ml/kg birth weight, was performed at 
a rate of 1.5 ml/minute. Once the infusion was complete the catheter was 
flushed with saline, the Rumels released and the catheter removed using 
digital pressure to provide hemostasis. After verification of hemostasis, the 
deep tissues, subcutaneous tissue and skin was apposed with running 4-0 
Monocryl. Recovery occurred on the operating room table until extubation. 
Postoperative distress or pain was managed by hydromorphone (0.2 mg/kg 
intramuscular injections) administered every 4 hours for 24 hours, and 
buprenorphine (0.03 mg/kg intramuscular injections, at 2000 hours) to 
provide overnight analgesia. Animals were housed in Biosafety Level 2 
facilities and in pairs when possible.
Necropsies and tissue dissection: Four weeks after virus administration, 
the four NHPs were euthanized following the recommendation from the 
Panel on Euthanasia of the American Veterinary Association. Each NHP 
was sedated with ketamine (10 mg/kg, intramuscular injection), given an 
overdose of barbiturate (25 mg/kg, intravenous injection) and killed by 
exsanguination. The brain was perfused through the ascending carotid 
artery with 1.5 l of heparinized saline solution (1 U/ml of heparin sodium, 
APP Pharmaceuticals, Schaumburg, IL, in 9.1 g NaCl/l) followed by 2.5 
l of 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) 
in PBS. Brains were removed from the skull and 4 mm coronal slabs, 
spanning the entire antero-posterior length of the brain were prepared 
using a monkey brain matrix (ASI Instruments, Warren, MI). Samples 
(1–2 cm3) from different peripheral organs were also collected and 
either stored at 85 °C for molecular analysis or fixed by immersion in 4% 
paraformaldehyde for IHC and co-IF analysis.
Immunolabeling and imaging of NHP samples: After 48 hours of 
fixation in freshly made PBS with 4% paraformaldehyde, brain slabs 
were transferred in 30% sucrose-PBS solution. Anterior, medial and 
posterior 4 mm coronal slabs were sectioned at 40 µm using a Microm 
(Thermo Fisher Scientific, Kalamazoo, MI) sliding microtome. Portions 
of the thoracic spinal cords and various peripheral organs (liver, heart/
ventricle, adrenals, kidney, spleen, testes) were also sectioned at 40 µm. 
GFP expression in these tissue samples was detected by IHC. Samples 
were washed in potassium phosphate-buffered saline (KPBS) buffer 
(0.02 mol/l, pH 7.4) and endogenous peroxidases were blocked by 
incubation for 30 minutes in KPBS-1% hydrogen peroxide, except for 
liver, spleen and kidney samples that were incubated in methanol-1% 
hydrogen peroxide. After three KPBS washes, sections were incubated 
for 30 minutes at room temperature in blocking solution (2% normal 
donkey serum, 0.5% Triton X-100, 0.02 mol/l KPBS), then incubated 
for 72 hours (brain sections) or 24 hours (all other samples) at 4 °C 
in primary antibody solution [2% normal donkey serum, 0.5% Triton 
X-100, 0.02 mol/l KPBS, goat anti-GFP (#ab6673, 1:1,500; Abcam, 
Cambridge, MA)]. After washing three times in 0.02 mol/l KPBS, 
secondary amplification was performed using a VectaStain ABC Elite 
Kit (#PK-6101; Vector Labs) with detection by diaminobenzidine 
tetrachloride (#D5905; Sigma, St Louis, MO) by itself or in conjunction 
with nickel sulfate hexahydrate (#N4882; Sigma). Stained sections were 
mounted on gelatin-coated slides and counterstained by incubation in a 
solution of 0.1% Cresyl Violet and 2.5% glacial acetic acid. Sections were 
then dehydrated and mounted in DPX mounting media.
For co-labeling studies, blocking and primary antibody incubations 
were done as described above. After washing, the sections were incubated 
for 1 hour at room temperature in secondary antibody solution (0.5% 
Triton X-100, 0.02M KPBS, secondary antibodies), then washed three more 
times in 1× PBS. Primary antibodies were as follows, with combinations 
described in Figure 8: goat anti-GFP (1:1,500, # ab6673; Abcam), mouse 
anti-glial fibrillary acidic protein (1:10,000, G3893; Sigma) and mouse 
anti-NeuN (1:500, #MAB377; Millipore). Secondary antibodies were 
used at 1:500 dilution and were: donkey anti-goat Alexa 488 (#A11055; 
Invitrogen) and goat anti-mouse Alexa 568 (#A11037; Invitrogen).
Simple IHC pictures were taken on a Zeiss Axioplan (Carl Zeiss 
Microimaging, Jena, Germany) coupled to a Retiga2000R camera managed 
by QCapture software (Qimaging, Surrey, BC, Canada). Imaging of double 
IHF was performed using a Zeiss Axio Imager 2 microscope linked to an 
Olympus DP71 camera managed by DP Controller software (v3.2.1.276, 
Olympus, Center Valley, PA).
NHP neutralizing antibody titer: HeLa RC32 cells (catalog # CRL-
2972; ATCC, Manassas, VA) were seeded at 3 × 104 cells/well in a 
48-well plate in Dulbecco’s modified Eagle’s medium with 10% fetal 
bovine serum and used the following day for the NAb experiment, at 
~50% confluence. Serum samples from the NHP taken at preinjection 
(0 weeks), 1, 2, and 4 weeks were each serially diluted 1:2 in PBS. Ten 
microliters of each serum dilution was mixed with 10 µl of scAAV9/CBh-
GFP (1.5 × 109 vg in PBS), then incubated for 2 hours at 4 °C. The AAV9/
serum solution was mixed with 100 µl of adenovirus (5 × 105 infectious 
units) in Dulbecco’s modified Eagle’s medium and immediately added 
to the HeLa RC32 cells. After incubation at 37 °C for 48 hours, cells 
were visualized for GFP expression. The NAb titer reported is the serum 
dilution showing a 50% decrease in the number of GFP positive cells.
suPPleMentArY MAterIAl
Figure S1. Comparison of AAV1, 5, 6, 8, and 9 for intravenous deliv-
ery to the mouse CNS with mannitol.
Figure S2. IHC of non-transduced CNS tissue.
Figure S3. Enlarged image of Figure 1c, right panel.
Figure S4. Enlarged image of Figure 1d, right panel.
Figure S5. Enlarged image of Figure 1e, right panel.
Figure S6. Darker exposure (DAB reaction) of a different hippocam-
pus slice portrayed in Figure 1b, right panel.
Figure S7. Darker exposure (DAB reaction) of a different striatum 
slice portrayed in Figure 1c, right panel.
Figure S8. Darker exposure (DAB reaction) of a different cerebellum 
slice portrayed in Figure 1d, right panel.
Figure S9. ssAAV9 can transduce the mouse CNS, but at a much 
lower efficiency.
Figure S10. Astrocyte transduction in NHPs.
Figure S11. Neuron transduction in NHPs.
Figure S12. Staining of neuron-like cells in i.c. versus i.v. injected 
NHPs.
Table S1. Fold differences and P values corresponding to Figure 1a.
Table S2. Neuron versus astrocyte counts in mice and nonhuman 
primates.
Table S3. Vector persistence in the serum of injected nonhuman 
primates.
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Table S4. AAV-packaged constructs used.
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